Kentucky Retirement Systems bought a new position in Solventum Co. (NYSE:SOLV – Free Report) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 10,412 shares of the company’s stock, valued at approximately $551,000.
Other institutional investors have also recently made changes to their positions in the company. Deseret Mutual Benefit Administrators bought a new stake in Solventum in the 2nd quarter worth about $25,000. Partnership Wealth Management LLC bought a new stake in shares of Solventum in the second quarter worth approximately $26,000. Richard W. Paul & Associates LLC purchased a new position in shares of Solventum during the second quarter valued at approximately $26,000. Family Firm Inc. bought a new position in Solventum during the second quarter valued at approximately $26,000. Finally, M&R Capital Management Inc. purchased a new stake in Solventum in the second quarter worth approximately $27,000.
Solventum Stock Performance
Shares of SOLV stock opened at $69.95 on Friday. The company has a debt-to-equity ratio of 2.90, a quick ratio of 0.96 and a current ratio of 1.31. The company’s fifty day moving average price is $61.01. Solventum Co. has a one year low of $47.16 and a one year high of $96.05.
Analysts Set New Price Targets
SOLV has been the topic of several research analyst reports. BTIG Research initiated coverage on Solventum in a report on Thursday, September 5th. They set a “neutral” rating on the stock. Wells Fargo & Company reduced their price target on shares of Solventum from $69.00 to $64.00 and set an “equal weight” rating for the company in a research report on Friday, August 9th. Bank of America cut their target price on shares of Solventum from $70.00 to $60.00 and set a “neutral” rating for the company in a research report on Tuesday, June 25th. The Goldman Sachs Group increased their price target on shares of Solventum from $48.00 to $54.00 and gave the stock a “sell” rating in a research report on Monday, August 12th. Finally, Morgan Stanley decreased their target price on Solventum from $70.00 to $55.00 and set an “equal weight” rating on the stock in a report on Monday, July 15th. One equities research analyst has rated the stock with a sell rating and six have given a hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $58.25.
Read Our Latest Report on SOLV
Solventum Company Profile
Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.
Read More
- Five stocks we like better than Solventum
- ETF Screener: Uses and Step-by-Step Guide
- Take Advantage of Village Farms Stock as Cannabis Market Evolves
- 3 Warren Buffett Stocks to Buy Now
- MarketBeat Week in Review – 9/16 – 9/20
- Consumer Staples Stocks, Explained
- Don’t Miss These 3 Retail Stocks for Fall Gains
Want to see what other hedge funds are holding SOLV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Solventum Co. (NYSE:SOLV – Free Report).
Receive News & Ratings for Solventum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solventum and related companies with MarketBeat.com's FREE daily email newsletter.